As per reports, Biotech giant Amgen Inc.’s (AMGN) experimental obesity drug currently known as AMG133 displayed promising durability trends in an early trial, leading way for a larger mid-stage study due early next year. Phase, I trial showed that those administered with the highest tested dose of the drug maintained their weight loss for 70 days. On record, at 150 days after the last dose was administered, maintained weight loss slipped to 11.2% below the original weight at the start of the trial.
Some of the side effects included vomiting and nausea but were resolved within a couple of days after the first dose. According to the U.S. Centers for Disease Control and Prevention, more than 40% of the U.S. population is obese, costing nearly $173 billion annually. Obesity is a major cause of type 2 diabetes, heart disease, certain cancers, and other health complications.
